Is prestroke use of angiotensin-converting enzyme inhibitors associated with better outcome?

Neurology

Volumn 68, Issue 20, 2007, Pages 1687-1693

  Chitravas, N ^a   Dewey, H M ^b,c,e   Nicol, M B ^a,b   Harding, D L ^b   Pearce, D C ^a   Thrift, A G ^a,b,c,d  

^a FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c AUSTIN HEALTH   (Australia)

^d MONASH UNIVERSITY   (Australia)

^e HEIDELBERG REPATRIATION HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR; ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGED; ARTICLE; AUSTRALIA; CEREBROVASCULAR ACCIDENT; CLAUDICATION; CONFIDENCE INTERVAL; DEATH; DIABETES MELLITUS; DISEASE SEVERITY; DRUG USE; FEMALE; GROUPS BY AGE; HEART ATRIUM FIBRILLATION; HEART FAILURE; HUMAN; HYPERTENSION; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; NEUROLOGIC DISEASE; NEUROPROTECTION; POPULATION RESEARCH; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; RISK REDUCTION; TIME OF DEATH; TRANSIENT ISCHEMIC ATTACK;

AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTICOAGULANTS; ANTIHYPERTENSIVE AGENTS; BRAIN DAMAGE, CHRONIC; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASES; COHORT STUDIES; COMORBIDITY; CONFOUNDING FACTORS (EPIDEMIOLOGY); DIURETICS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; ODDS RATIO; PLATELET AGGREGATION INHIBITORS; PROGNOSIS; RISK; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; TIME FACTORS; VICTORIA;

EID: 34248596325     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000261914.18101.60     Document Type: Article

References (28)

1. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342:145-153.
2. Svensson P, de Faire U, Sleight P, Yusuf S, Ostergren J. Comparative effects of ramipril on ambulatory and office blood pressures: a HOPE Substudy. Hypertension 2001;38:E28-E32.
3. Werner C, Hoffman WE, Kochs E, Rabito SF, Miletich DJ. Captopril improves neurologic outcome from incomplete cerebral ischemia in rats. Stroke 1991;22:910-914.
4. Selim M, Savitz S, Linfante I, Caplan L, Schlaug G. Effect of pre-stroke use of ACE inhibitors on ischemic stroke severity. BMC Neurol 2004;5:10-14.
5. Bosch J, Yusuf S, Pogue J, et al. Use of ramipril in preventing stroke: double blind randomised trial. BMJ 2002;324:699-702.
6. Hansson L, Lindholm LH, Niskanen L, et al. Effect of angiotensin- converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999;353:611-616.
7. Fournier A, Messerli FH, Achard JM, Fernandez L. Cerebroprotection mediated by angiotensin II: a hypothesis supported by recent randomized clinical trials. J Am Coll Cardiol 2004;43:1343-1347.
8. Klungel OH, Heckbert SR, Longstreth WT, et al. Antihypertensive drug therapies and the risk of ischemic stroke. Arch Intern Med 2001;161:37-43.
9. Medical Research Council trial of treatment of hypertension in older adults: principal results. MRC Working Party. BMJ 1992;304:405-412.
10. Ovbiagele B, Kidwell CS, Starkman S, et al. Angiotensin 2 type 2 receptor activity and ischemic stroke severity. Neurology 2005;65:851-854.
11. Thrift AG, Dewey HM, Sturn JW, et al. Greater incidence of both fatal and nonfatal strokes in disadvantaged areas: the Northeast Melbourne Stroke Incidence Study. Stroke 2006;37:877-882.
12. Thrift AG, Dewey HM, Macdonell RAL, et al. Incidence of the major stroke subtypes: initial findings from the North East Melbourne Stroke Incidence Study (NEMESIS). Stroke 2001;32:1732-1738.
13. Sudlow CL, Warlow CP. Comparing stroke incidence worldwide: what makes studies comparable? Stroke 1996;27:550-558.
14. Brott T, Adams HP, Olinger CP, et al. Measurements of acute cerebral infarction: a clinical examination scale. Stroke 1989;20:864-870.
15. Kasner SE, Chalela JA, Luciano JM, et al. Reliability and validity of estimating the NIH stroke scale score from medical records. Stroke 1999;30:1534-1537.
16. Hatano S. Experience from a multicentre stroke register: a preliminary report. Bull World Health Organ 1976;54:541-553.
17. Bamford J, Sandercock P, Dennis M, Burn J, Warlow C. Classification and natural history of clinically identifiable subtypes of cerebral infarction. Lancet 1991;337:1521-1526.
18. Frankel MR, Morgenstern LB, Kwiatkowski T, et al. Predicting prognosis after stroke: a placebo group analysis from the National Institute of Neurological Disorders and Stroke rt-PA Stroke Trial. Neurology 2000;55:952-959.
19. Ruiz-Ortega M, Lorenzo O, Suzuki Y, Ruperez M, Egido J. Proinflammatory actions of angiotensins. Curr Opin Nephrol Hypertens 2001;10:321-329.
20. Weiss D, Sorescu D, Taylor WR. Angiotensin II and atherosclerosis. Am J Cardiol 2001;87:25C-32C.
21. Dimmeler S, Rippmann V, Weiland U, Haendeler J, Zeiher AM. Angiotensin II induces apoptosis of human endothelial cells: protective effect of nitric oxide. Circ Res 1997;81:970-976.
22. Sadoshima J. Cytokine actions of angiotensin II. Circ Res 2000;86:1187-1189.
23. Fernandez LA, Spencer DD, Kaczmar T Jr. Angiotensin II decreases mortality rate in gerbils with unilateral carotid ligation. Stroke 1986;17:82-85.
24. Iwai M, Liu HW, Chen R, et al. Possible inhibition of focal cerebral ischemia by angiotensin II type 2 receptor stimulation. Circulation 2004;110:843-848.
25. Maktabi MA, Todd MM, Stachovic G. Angiotensin II contributes to cerebral vasodilatation during hypoxia in the rabbit. Stroke 1995;26:1871-1876.
26. Smith MA, Doliszny KM, Shahar E, McGovern PG, Arnett DK, Luepker RV. Delayed hospital arrival for acute stroke: the Minnesota Stroke Survey. Ann Intern Med 1998;129:190-196.
27. Jorgensen HS, Nakayama H, Reith J, Raaschou HO, Olsen TS. Factors delaying hospital admission in acute stroke: the Copenhagen Stroke Study. Neurology 1996;47:383-387.
28. Bruno A, Biller J, Adams HP Jr, et al. Acute blood glucose level and outcome from ischemic stroke. Trial of ORG 10172 in Acute Stroke Treatment (TOAST) Investigators. Neurology 1999;52:280-284.